News from Visiopharm


New APP: PD-L1 Melanoma

Programmed death-ligand 1 (PD-L1) is a transmembrane protein that binds to the inhibitory receptor programmed death 1 receptor (PD-1), causing a down regulation of immune responses. Tumor cells can upregulate PD-L1 expression and avoid being attacked by the body’s immune system, making an interruption of the PD-1/PD-L1 interaction an attractive method for assisting the immune system in destroying tumor cells.

For more information visit our APP Center

Short Course on Quantitative Digital Pathology

October 23-27, 2017

Attend our Short Course on Quantitative Digital Pathology

Read more here

 

 

New APP: PD-L1 Lung Cancer

PD-L1 is typically expressed on normal cells but has been observed in immune cells and tumor cells while PD-1 is typically expressed on cytotoxic T-cells and other immune cells. Tumor cells can upregulate PD-L1 expression and avoid being attacked by the body’s immune system, making an interruption of the PD-1/PD-L1 interaction an attractive method for assisting the immune system in destroying tumor cells.

For more information visit our APP Center

New APP: PD-L1+SOX10, Melanoma, TME

SOX10 is a nuclear transcription factor that has been shown to be a sensitive and specific marker for malignant melanoma. Combining SOX10 and PD-L1 enables the user to assess whether PD-L1 expression originates from tumor cells or adjacent non-tumor cells.

This APP can be used to determine the number of tumor and non-tumor cells that express PD-L1 without having to outline tumor regions.

For more information visit our APP Center

Sign up to our newsletter
* indicates required
Are you a current customer
 

Visiopharm quantitative digital pathology solutions provide pathologists and scientists with a flexible, powerful suite of software to quantify relevant tissue properties in a fast, objective and reproducible way.

Learn more about us

Visit our APP center

The worlds largest and fastest growing

Visit the complete app center

Publications

Visiopharm software is featured in over 1200 international scientific publications. They are based on collaborations with leading scientists in hospitals, biopharmaceutical companies and research institutions around the world. Select a main category to access the publication list.